Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
|
| |||
| |||
Ablynx NV* |
Procter & Gamble Pharmaceuticals Inc. |
Ablynx will use its Nanobody platform to discover and develop candidates against a GPCR target specified by P&G |
Ablynx gets R&D funding and potential milestone and royalty payments; P&G is responsible for any development and sales (7/19) |
| |||
Acorda |
Elan Corp. plc (Ireland) |
Acorda acquired U.S. rights to Zanaflex (tizanidine), a drug marketed for spasticity |
The deal includes a newer, approved capsule formulation; Elan will supply the capsule, and retains its manufacturing rights; terms of the deal were not disclosed (7/28) |
| |||
Acusphere |
Nycomed Group (Denmark) |
Nycomed got European rights to AI-700, an ultrasound contrast agent in Phase III trials |
Acusphere gets $12M in up-front and research payments over two years and up to $58M in regulatory and sales milestones, as well as royalties on any sales (7/7) |
| |||
Advancis |
Eli Lilly and Co. |
Advancis acquired U.S. rights to the Keflex brand of cephlexin, an antibiotic with 2003 sales of $4M |
Advancis paid Lilly $11M for the exclusive rights; it plans to apply its Pulsys delivery technology to develop the product further (7/1) |
| |||
Alnylam |
Merck & Co. Inc. |
Deal to develop and sell RNAi therapeutics for ocular diseases, the second collaboration between the companies |
Alnylam gets an up-front payment and milestones totaling up to $19.5M; they will share costs and revenues; Alnylam has a co-promotion option for the U.S. (6/30) |
| |||
Ambit |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche will use Ambit's kinase- screening platform to profile and select small-molecule kinase inhibitors |
Ambit could receive milestone payments and royalties on resulting drugs; concurrently, Roche led Ambit's $21M Series C financing (8/26) |
| |||
Anadys |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Anadys will apply its drug discovery capabilities to help advance an undisclosed Roche compound |
Under the third deal between the companies, Anadys will get R&D funding and potential milestones and royalties on the product (7/29) |
| |||
Anika |
Ortho Neutrogena Division (unit of Johnson & Johnson) |
Exclusive worldwide deal on Anika's hyaluronic acid-based cosmetic tissue-augmentation therapy |
Anika gets $1M up front and milestones upon approval in the U.S. and Europe, as well as for hitting sales and development targets; Anika also would get royalty and transfer payments; Ortho will fund the ongoing Phase III trial and other R&D (7/26) |
| |||
Antisoma plc |
EMD Lexigen Research Center Corp. (affiliate of Merck KGaA; Germany) |
Antisoma gained exclusive rights to BC1-IL12 after acquiring EMD's half-stake |
Antisoma plans to accelerate development of the preclinical cancer drug, which now will be known as AS1409; terms were not disclosed (7/26) |
| |||
Aphton Corp. |
Daiichi Pure Chemicals Co. Ltd. (Japan) |
Collaboration to develop and sell gastrin-related diagnostic kits for gastrointestinal cancers |
Daiichi will develop the kits and have worldwide manufacturing and supply rights; Aphton has commercialization rights outside Asia (6/23) |
| |||
Ascend |
Besins International Holdings |
Ascend got exclusive North American rights to Andrin (transdermal dihydrotesosterone gel) |
Andrin, which is being tested for low testosterone levels in older men, uses Ascend's EHG gel technology; terms were not disclosed (7/7) |
| |||
Bavarian |
GlaxoSmithKline plc (UK) |
GSK will manufacture and market Bavarian's Imvamune smallpox vaccine to most international markets |
Bavarian retains responsibility for a contract with the NIH; the companies will collaborate on future U.S. government programs; terms were not disclosed (7/15) |
| |||
Benitec Ltd. |
Merck & Co. Inc. |
Merck got a nonexclusive worldwide research license to practice DNA-directed RNAi technology |
The license does not cover downstream commercial rights for therapeutic development; terms were not disclosed (7/5) |
| |||
BioDelivery |
Sigma-Tau SpA (Italy) |
Understanding on deal for Sigma-Tau to use BDSI formulation and delivery technology with different compounds, with a focus in oncology |
Under the proposed license, BDSI would get $250,000 up front and $750,000 for milestones leading to the first IND; BioDelivery then could earn milestones and royalties on sales (7/28) |
| |||
Biomax |
Siemens AG (Germany) |
Collaboration in the area of gene- expression modeling and simulation |
They are combining Siemens' BioSim product with Biomax's BioXm expression analysis tool; terms were not disclosed (8/18) |
| |||
Biovation |
Pfizer Inc. |
Biovation will apply its immunogenicity technology to drugs designed by Pfizer |
Biovation will receive research revenues; further terms were not disclosed (8/12) |
| |||
Bioventix |
Roche Diagnostics (Switzerland) |
Bioventix licensed sheep monoclonal antibodies to Roche |
Roche will use the antibodies in the development of diagnostic products; terms were not disclosed (8/18)** |
| |||
Celera |
Merck & Co. Inc. |
Deal to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease |
Merck will fund research at Celera and make certain clinical milestone payments, as well as royalties on any resulting sales; Merck gets rights for therapeutic applications in Alzheimer's disease and for certain other neurological disorders, while Celera retains diagnostic rights (7/28) |
| |||
Celera |
General Electric Co. |
Collaboration to accelerate discovery and development of products for personalized medicine |
The first project supports GE's development of imaging agents for cancer, and the second is in bioinformatics; specific terms of the deal were not disclosed (7/12) |
| |||
Celera |
Abbott Laboratories |
Deal to develop antibodies and small molecules against overexpressed cell-surface proteins associated with cancer |
Abbott will screen protein antigens identified by Celera; the companies would either jointly share costs and revenues, or work under a milestone and royalty structure; Celera also could get milestone payments (7/7) |
| |||
Cellegy |
Strakan Pharmaceuticals Ltd. (UK) |
Strakan gained responsibility for registering and selling the transdermal testosterone gel Tostrex in Europe |
Cellegy could receive up to $5.75M in up-front and milestone payments, along with a double-digit royalty on sales; the product is being reviewed in Sweden (7/13) |
| |||
Cellomics Inc.* |
GE Healthcare |
Deal to develop an interface that permits high-content screening analysis |
Cellomics will develop and sell software that combines GE's subcellular imaging instruments and Cellomics' high-content informatics platform (6/29) |
| |||
Cellomics Inc.* |
GE Healthcare (unit of General Electric Co.) |
Nonexclusive worldwide license deal covering Cellomics' high- content screening technology |
They also entered a limited-term deal under which GE will broker sublicense deals for the technology; terms were not disclosed (6/22) |
| |||
Cepheid Inc. |
Roche Diagnostics (Switzerland) |
Cepheid gets nonexclusive worldwide rights to PCR-related patents in the field of in vitro human diagnostics |
Roche gets a license fee and royalties on any covered products; the deal excludes human identity testing and detecting pathogens for blood-bank screening and plasma fractionation (6/24) |
| |||
Cerus Corp. (CERS) and |
BioOne Corp. |
Definitive agreement under which BioOne will commercialize the Intercept Blood System for platelets in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore |
Baxter and Cerus each received an up-front payment of $2.5M, and each would get Baxter another $7.5M upon approval of the deal by BioOne shareholders, as well as contingent milestones and royalties; as part of the deal, Cerus made a $1.2M equity investment in BioOne (7/29) |
| |||
Chemical |
Merck KGaA (Germany) |
CDL was selected as the preferred provider for screening libraries of lead-like small compounds |
The deal through 2006 has an extension option; they will determine compounds to be synthesized by CDL for early screening at Merck; terms were not disclosed (7/6) |
| |||
Chromos |
Centocor Inc. (unit of Johnson & Johnson) |
Chromos will develop cell lines for potential use in the clinical and commercial manufacture of two therapeutic proteins |
Chromos will use its Artificial Chromosome Expression System in the effort; Centocor will have the option to use the cell lines after the deal's research phase; terms were not disclosed (8/19) |
| |||
Codexis Inc.* |
Pfizer Inc. |
Nonexclusive collaboration involving process R&D for some of Pfizer's small-molecule human therapeutics |
The multiyear deal includes up-front payments, technology-access fees and milestones that could total $40M; Pfizer also is making a $10M equity investment; the deal involves multiple projects per year, each of which could generate additional payments to Codexis (7/26) |
| |||
Crucell NV |
Wyeth |
Wyeth licensed Crucell's PER.C6 cell line for preclinical adenoviral vector-based research and development |
Crucell gets an up-front payment and annual maintenance fees; further details were not disclosed (8/25) |
| |||
Crucell NV (the Netherlands; CRXL) and DSM Biologics (the Netherlands) |
GlaxoSmithKline plc (UK) |
GSK licensed Crucell's PER.C6 technology for preclinical use related to recombinant monoclonal antibody products |
Crucell and DSM get an up-front payment and annual maintenance fees; further terms were not disclosed (8/13) |
| |||
Deltanoid |
Abbott Laboratories |
Option and license deal for development of vitamin D receptor activators (VDRAs) for treating renal disease |
The deal continues a 20-year partnership in the area between Abbott, Hector DeLuca (now president and CEO of Deltanoid) and the University of Wisconsin; Abbott got rights to a new generation of VDRAs (7/22) |
| |||
Diversa Corp. |
GlaxoSmithKline plc (UK) |
Diversa will develop chemistry processes required to advance a GSK anti-infective compound into clinical development |
GSK gets an option to further develop the compound and obtain exclusive worldwide rights in exchange for milestone payments, option and license fees, and royalties to Diversa; if the option is not exercised, Diversa would pay royalties on any sales (7/19) |
| |||
DOV |
Merck & Co. Inc. |
Deal covering DOV's triple-uptake inhibitors being developed for depression and related psychiatric disorders |
Merck licensed exclusive worldwide rights to DOV 21,947, which is in Phase I, for all indications and to DOV 216,303 for depression, anxiety and addiction; DOV gets $35M up front, up to $300M in milestone payments and up to $120M for reaching sales thresholds, as well as royalties on any sales (8/5) |
| |||
Enanta |
Shionogi & Co. |
Collaboration to develop and sell Enanta's EP-013420 for respiratory tract infections in Japan and certain other countries in Asia |
Enanta gets an up-front payment and equity investment, and could earn undisclosed milestone and royalty payments; Enanta retains rights in the rest of the world to the compound, which is nearing Phase I trials (7/27) |
| |||
Enzo Biochem |
GlaxoSmithKline |
GSK gets a nonexclusive license to RNA/DNA labeling, detection and amplification technology |
The deal was made with Enzo subsidiary Enzo Life Sciences for generating genomic information; terms were not disclosed (7/20) |
| |||
Europroteome |
Altana Pharma AG (Germany) |
Deal to evaluate approaches to molecular profiling of tissue specimens from cancer patients |
Europroteome will use its collection of purified human cancer cells in the deal, terms of which were not disclosed (7/1) |
| |||
Evotec OAI |
Seikagaku Corp. (Japan) |
Collaboration to identify small- molecule therapeutics against Seikagaku targets in inflammatory diseases |
Evotec will develop assays and screen compounds, and further characterize those that are active; further details were not disclosed (8/11) |
| |||
GB |
Chiesi Farmaceutici SpA (Italy) |
GB licensed worldwide rights to Chiesi's CHF3381, which is being developed for treating neuropathic pain |
Phase II trials are expected to begin in 2Q:05; terms of the deal were not disclosed (8/10) |
| |||
GenData |
Battelle |
Collaboration to discover and develop biomarkers for diagnostic and therapeutic applications in chronic obstructive pulmonary disease |
GenData is providing access to its biomedical research repository; terms were not disclosed (8/12) |
| |||
GeneGo Inc.* |
Bristol-Myers Squibb Co. |
BMS licensed GeneGo's MetaCore data-mining suite |
Terms of the deal were not disclosed (8/10) |
| |||
Gene Logic |
NV Organon (the Netherlands) |
Organon will use Gene Logic's toxicogenomics platform to help assess and prioritize its preclinical pipeline |
Gene Logic will provide services for 18 months; Organon previously had licensed use of Gene Logic's GeneExpress System database (7/28) |
| |||
Generex |
Sejong Capital plc (South Korea) |
Entered letter of intent to form joint venture to sell Generex's Oralin and the RapidMist diabetes management system in India, China and Australia |
Sejong is investing $25M in the venture and purchasing $5M of Generex stock at $2.50 per share; Generex will own 51% of the joint venture (6/24); Sejong (now Charmed Capital plc) increased its equity commitment to $6M (8/25) |
| |||
Geron Corp. |
Procter & Gamble Co. |
P&G got a nonexclusive license to human telomerase reverse transcriptase technology |
The license covers research applications; P&G will study the regulation of cell function and develop biological assays for screening; terms were not disclosed (7/7) |
| |||
Halozyme |
Baxter Healthcare Corp. |
Baxter will sell Enhanze SC, Halozyme's recombinant human hyaluronidase enzyme, for certain indications in the U.S. and Puerto Rico |
They would be equal partners in the commercialization of the product, for which an NDA filing is expected in 1Q:05 for use as a spreading agent; they may negotiate on other territories; terms were not disclosed (8/16) |
| |||
Icagen Inc.* |
McNeil Consumer & Specialty Pharmaceuticals (unit of J&J) |
Deal to jointly develop and sell ICA-7043, which has completed Phase II trials in sickle cell disease |
Icagen gets an up-front payment and potential milestones; they will share expenses and profits in the U.S., and Icagen would get royalties on any non-U.S. sales (6/29) |
| |||
Icon Genetics |
Berlex Inc. (unit of Schering AG; Germany) |
Deal to evaluate expression levels and quality of certain Berlex preclinical proteins |
The candidates will be expressed in transgenic plants using Icon's magnICON bio-manufacturing platform technology; terms were not disclosed (8/17) |
| |||
Lexicon |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Deal to develop drugs for high blood pressure, building on work against hypertension targets discovered in Lexicon's Genome5000 program |
Takeda gets exclusive access to all drug targets from the program that control blood pressure, and takes over all development work and costs; Lexicon gets $12M for the original three-year term; Lexicon also can get research, development and launch milestones for each product, as well as royalties on sales (7/28) |
| |||
LifeSpan |
Undisclosed pharmaceutical company |
The company subscribed to LifeSpan's DrugTarget Database |
The deal is valued at $2M; the subscriber will nominate 50 additional genes for study and inclusion in the expanded database over a two-year period (8/23) |
| |||
Locus |
Procter & Gamble |
Collaboration to design new drugs for treating diabetes, based on a P&G target |
Locus gets an up-front fee and research support to fully identify and characterize all binding sites on the target protein; Locus will design molecules, to which P&G could gain rights in exchange for milestones and royalties (7/26) |
| |||
Medinox Inc.* |
PUMC Pharmaceutical Co. (China) |
PUMC will be responsible for selling NOX-100 for treating septic shock patients in China and South Korea |
Medinox could receive milestone payments and royalties on any sales; the product, also named Norathiol, has completed Phase I/II trials (8/16) |
| |||
Memory |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Extended by two years their PDE4 collaboration that began in 2002 |
Under the extension, Roche committed at least 18 months and $5.25M in research funding for Memory (8/10) |
| |||
Merix |
Kirin Brewery Co. Ltd. (Japan) |
Collaboration to develop dendritic-cell vaccines in multiple indications, starting with cancer and HIV |
Kirin made an equity investment in Merix; they will jointly develop products and would share profits; Merix would market products in the U.S. and Kirin in Asia, with Europe to be decided (6/22) |
| |||
Microbix |
GE Healthcare (UK) |
Microbix will develop recombinant adenoviruses for use with GE's subcellular imaging systems |
Terms of the contract were not disclosed (7/26) |
| |||
Micrologix |
Strata Pharmaceuticals Inc. |
Deal to develop MBI-226, a compound in Phase III trials for preventing catheter- related infections |
Strata gets exclusive rights in North America and Europe; Micrologix gets $2M up front and up to $30M in milestones, as well as a double-digit royalty on any sales; Strata takes over responsibility for further development and manufacturing (8/3) |
| |||
Micromet |
Merck & Co. Inc. |
Merck got a research license to patents on single-chain antibodies held by Micromet and Enzon Pharmaceuticals Inc. |
Micromet gets an up-front payment and annual maintenance fees, which will be shared with Enzon (7/15) |
| |||
Millennium |
GlaxoSmithKline plc (UK) |
GSK will exclusively market Integrilin in Europe, following reacquisition of those rights from Schering-Plough Corp. |
Millennium is entitled to license fees, milestone payments and royalties on sales in Europe; the terms with Schering-Plough remain in place outside Europe (6/23) |
| |||
Miravant |
Guidant Corp. |
Collaboration on Miravant's PhotoPoint cardiovascular programs |
Guidant is providing $3M up front and up to $7M in support, as well as milestones through Phase I trials; details on rights were not disclosed (7/6) |
| |||
ML Laboratories |
Unnamed company |
Deal to develop a combination of two established respiratory medications in ML's C200 dry-powder inhaler |
ML's respiratory division Innovata Biomed could get £7.5M (US$13.7M) in access fees and milestones; it also could get £9M in development fees, as well as royalties on sales (6/24) |
| |||
MorphoSys |
Centocor Inc. (unit of Johnson & Johnson) |
Centocor exercised an option to retain a commercial license for HuCAL antibodies directed against a Centocor target in inflammatory diseases |
MorphoSys gets an undisclosed license payment; the collaboration began in December 2000 and includes a Centocor option on development of antibodies against up to 30 different target molecules (8/25) |
| |||
MorphoSys |
Boehringer Ingelheim GmbH (Germany) |
Deal to develop a therapeutic antibody against an undisclosed target molecule involved in cardiovascular diseases |
MorphoSys will generate the antibody, which BI will develop and market; MorphoSys can get milestone and royalty payments; BI exercised its option to use MorphoSys technology under a February 2003 deal (8/16) |
| |||
Morphotek Inc.* |
Baxter Healthcare Corp. |
Baxter will support development and manufacturing of a Morphotek antibody |
The product is Morphotek's lead cancer therapeutic antibody, MORAb-003; terms of the deal were not disclosed (8/10) |
| |||
Nabi |
DSM Pharmaceuticals Inc. |
Nabi exercised its option to acquire full rights to Aloprim |
The intravenous form of allopurinol is marketed to help control elevated uric acid levels; Nabi has had U.S. distribution rights since 1999 (6/30) |
| |||
Nektar Therapeutics (NKTR) |
Pfizer Inc. |
Pfizer will apply Nektar's pegylation technology to a product under development |
Nektar will receive milestone and manufacturing payments, as well as royalties on any sales; Enzon Pharmaceuticals Inc. would get a share of any Nektar royalties or profits (8/2) |
| |||
NexMed Inc. |
Schering AG |
Schering got rights to Alprox-TD in Europe, Russia, Australia, the Middle East, South Africa and New Zealand |
NexMed is eligible to receive milestone payments and to share revenue from any sales of the erectile dysfunction cream treatment in the covered territories (7/6) |
| |||
NicOx SA |
Pfizer Inc. |
Pfizer gained an option to license worldwide rights to early stage nitric oxidedonating compounds in an undisclosed field |
NicOx gets €1M up front and another €1M in six months; it would get €35M in milestone payments if a product is commercialized, as well as royalties on sales (8/26) |
| |||
Norak Biosciences |
H. Lundbeck A/S (Denmark) |
Lundbeck exercised its option to screen another GPCR target of interest using Norak's Transfluor technology |
The option was covered in their December 2002 agreement; terms were not disclosed (8/10) |
| |||
Optimer |
Nippon Shinyaku Co. Ltd. (Japan) |
Optimer acquired exclusive rights to develop and sell prulifloxacin in the U.S. |
Prulifloxacin is a fluoroquinolone antibiotic on the market in Japan; terms of the deal were not disclosed (6/28) |
| |||
Paion GmbH* |
Forest Laboratories Inc. |
Deal covering the U.S. and Canada for Paion's plasminogen activator desmoteplase, which has completed Phase II trials |
Paion got an up-front payment and could get milestones and royalties; Forest will fund development in its licensed countries; Paion retains rights in the rest of the world (7/6) |
| |||
Palatin |
King Pharmaceuticals Inc. |
Deal to commercialize Palatin's Phase II product PT-141 for treating male and female sexual dysfunction |
Palatin gets $20M up front, including a $5M equity investment, and up to $100M in development and regulatory milestones; another $130M could be paid if sales targets are met; they will share costs and revenues in North America, and share any revenues from collaborators elsewhere (8/13) |
| |||
ProMetic Life |
GlaxoSmithKline |
ProMetic will provide GSK access to its affinity purification technology |
ProMetic will develop affinity materials and purification process steps for proteins of interest to GSK; terms were not disclosed (7/6) |
| |||
Replidyne Inc.* |
Daiichi Suntory Pharma (Japan) |
Replidyne obtained rights to faropenem daloxate, a clinical compound for bacterial infections |
Daiichi gets undisclosed up-front and potential milestone and royalty payments; Replidyne's rights are exclusive in the U.S. and Canada, and it has an exclusive option to everywhere else but Japan (8/17) |
| |||
SanguiBioTech |
German pharmaceutical company |
Companies intend to develop a hemoglobin wound spray for chronic wounds based on Sangui's artificial oxygen carrier |
The deal was expected to be signed in August; the pharmaceutical company would market the product worldwide and pay BioTech royalties on any sales (6/21) |
| |||
Structural |
Shire Biochem Inc. (Canada) |
SGX acquired worldwide rights to Troxatyl, an agent in Phase I/II trials for acute myelogenous leukemia |
SGX will make an undisclosed up-front payment, and make potential milestone and royalty payments; it plans to move into Phase II in early 2005 (7/29) |
| |||
Sunesis |
Merck & Co. Inc. |
Collaboration to discover oral drugs for viral infections; Sunesis will supply a series of compounds for the effort |
Sunesis gets an up-front payment and annual license fees, as well as potential milestones and royalties; Merck gets worldwide rights and is responsible for development (7/27) |
| |||
SurroMed Inc.* |
Merck & Co. Inc. |
SurroMed will analyze pre-clinical samples from Merck using proteomics technology |
The companies expanded and extended the previously undisclosed deal on biological marker discovery; terms were not disclosed (7/7) |
| |||
TransForm |
Eli Lilly and Co. |
TransForm will use its informatics technologies to conduct formulation work on preclinical candidates |
TransForm will retain rights to use any new tools developed in the work; terms of the deal were not disclosed (7/28) |
| |||
Transition |
Novo Nordisk |
Novo exercised its option from November 2003 to license Transition's Islet Neogenesis Therapy for diabetes |
Transition gets a $4.6M equity investment and up to $48M in up-front and development milestone payments, as well as potential commercial milestones and royalties; Novo gets worldwide rights (8/23) |
| |||
Vernalis |
Novartis Institutes for BioMedical Research Inc. |
Novartis exercised its option to license exclusive worldwide rights to Vernalis' Hsp90 oncology program |
Novartis will pay $1.5M up front and make a $9M equity investment for about 4.6% of Vernalis; including milestones, total payments to Vernalis could exceed $75M if two products reach market; it also would get royalties on sales (8/9) |
| |||
Vertex |
Merck & Co. Inc. |
Global deal to develop and sell VX-680, Vertex's lead Aurora kinase inhibitor, which is nearing clinical trials in cancer |
Vertex gets $20M up front, $14M in research funding over two years, and up to $350M in milestones, including $130M for approval in the first cancer indication; Merck had development and marketing responsibilities and would pay royalties; Vertex has a co-promotion option; they also will research follow-on compounds and applications outside oncology (6/22) |
| |||
ViroPharma |
Schering-Plough Corp. |
Schering-Plough exercised its option to license pleconaril in the U.S. and Canada for treatment of the common cold |
ViroPharma gets a $10M license fee and up to $65M in regulatory and commercial milestone payments, as well as royalties on any sales; the option stems from a November 2003 deal on an intranasal form of the drug (8/23) |
| |||
ZymoGenetics |
Novo Nordisk A/S (Denmark) |
Novo licensed rights outside the U.S. to interleukin-28A, IL-29 and IL-31, under an existing option agreement |
ZymoGenetics gets license fees along with undisclosed potential milestone and royalty payments; the technology could have applicability in viral infections and cellular infiltration and inflammation (7/6) |
|
|
|
|
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes date item ran in BioWorld International. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
